Healthcare utilization and direct medical cost in the years during and after cancer diagnosis in patients with type 2 diabetes mellitus

Autor: Cindy L. K. Lam, Fan Yang, Wendy W L Chan, Tingting Wu, Carlos K. H. Wong
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
Pediatrics
medicine.medical_specialty
Endocrinology
Diabetes and Metabolism
Population
030209 endocrinology & metabolism
Type 2 diabetes
Diseases of the endocrine glands. Clinical endocrinology
Insurance Claim Review
03 medical and health sciences
0302 clinical medicine
Neoplasms
Diabetes mellitus
Internal Medicine
medicine
Humans
In patient
education
Aged
Retrospective Studies
Cancer
education.field_of_study
Type 2 diabetes mellitus
business.industry
Type 2 Diabetes Mellitus
Retrospective cohort study
Articles
Health Care Costs
General Medicine
Patient Acceptance of Health Care
Prognosis
medicine.disease
RC648-665
Direct medical costs
Hospitalization
Clinical Science and Care
Diabetes Mellitus
Type 2
Case-Control Studies
030220 oncology & carcinogenesis
Life expectancy
Original Article
Female
business
Follow-Up Studies
Zdroj: Journal of Diabetes Investigation, Vol 11, Iss 6, Pp 1661-1672 (2020)
Journal of Diabetes Investigation
ISSN: 2040-1116
2040-1124
Popis: Aims/Introduction There is uncertainty about the direct medical costs of type 2 diabetes patients with cancers. Materials and Methods A population‐based retrospective cohort of 99,915 type 2 diabetes patients from the Hong Kong Hospital Authority between 2006 and 2017 was assembled. A total of 16,869 patients who had an initial cancer diagnosis after type 2 diabetes diagnosis were matched with 83,046 patients without cancer (controls) using a matching ratio of up to one‐to‐five propensity score‐matching method. Patients were divided into four categories according to life expectancy. Healthcare service utilization and direct medical costs during the index year, subsequent years and mortality year were compared between patients with and without cancer in each category. Results Medical costs of cancer patients in the index year ranged from $US27,533 for patients who died in 3 years. Cancer patients had significantly greater expenditures than controls in the index year (all P 3 years after the index year ($US32,558 vs $US28,260). For patients in both groups, patients who survived >3 years had significantly lower costs than those who died in 90% of the medical costs for both groups in the mortality year. Conclusions Type 2 diabetes patients with cancers incurred greater medical costs in the diagnosis, ensuing and mortality years than type 2 diabetes patients without cancers.
Type 2 diabetes increases the risks of cancers, which have a tremendously heavy economic burden. Type 2 diabetes patients with cancers had significantly greater costs in the cancer diagnosis year, ensuing years and mortality year. Current type 2 diabetes economic models can be further refined by incorporating cancer as a model event subgraph (b), the p‐value for year of mortality should be 0.594 instead of p < 0.001.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje